secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0001104659-24-115850
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Q3 net loss $2.3M; initiates Peeling Skin Syndrome study; management buys shares
--------------------------------------------------------------------------------

- Net loss of $2.3M for Q3 2024 vs $1.9M in Q3 2023; nine-month net loss $6.7M vs $6.6M.
- Cash and equivalents $10.3M as of Sept 30, 2024; expected to fund operations into late 2025.
- Initiates investigator-led clinical study for QRX003 in Peeling Skin Syndrome in New Zealand; no approved treatments exist.
- Opens two additional UK sites for Netherton Syndrome trials under FDA IND; plans further European expansion.
- Entire management team made significant insider share purchases in September, signaling confidence in growth trajectory.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465924115850/0001104659-24-115850-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465924115850/tm2427874d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-115850

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer